|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
dioctanoylphosphatidic acid results in increased expression of PTGS2 protein |
CTD |
PMID:11854442 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of ACTA2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:14769825 PMID:17550345 PMID:20103642 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] |
CTD |
PMID:10698703 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein |
CTD |
PMID:19646460 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of BCAR1 protein |
CTD |
PMID:11792571 |
|
NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein |
CTD |
PMID:23251428 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C5 |
complement C5 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of HC protein |
CTD |
PMID:25822713 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] |
CTD |
PMID:23251428 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased expression of CCN2 protein N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] |
CTD |
PMID:15200425 PMID:24706986 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of COL1A2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of CSF1 protein |
CTD |
PMID:25822713 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL16 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO |
lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] lysophosphatidic acid results in decreased expression of CXCR1 mRNA |
CTD |
PMID:16224106 |
|
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
multiple interactions |
ISO |
DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:14769825 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions decreases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 PMID:25896349 More...
|
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
multiple interactions |
ISO |
FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein] |
CTD |
PMID:18642114 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gna13 |
G protein subunit alpha 13 |
multiple interactions |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr10:94,337,939...94,370,774
Ensembl chr10:94,337,725...94,370,774
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein] [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein |
CTD |
PMID:17919812 PMID:22537771 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases phosphorylation |
EXP |
MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein] |
CTD |
PMID:20864298 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
lysophosphatidic acid results in increased secretion of IL6 protein |
CTD |
PMID:21821728 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
KNG1 protein inhibits the reaction [[Wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMA3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMB3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMC2 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
increases response to substance multiple interactions |
ISO |
LPAR1 protein results in increased susceptibility to lysophosphatidic acid LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] |
CTD |
PMID:16224106 PMID:16809448 PMID:25398768 |
|
NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895
|
|
G |
Lpar3 |
lysophosphatidic acid receptor 3 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein |
CTD |
PMID:30102254 |
|
NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
|
|
G |
Lpar5 |
lysophosphatidic acid receptor 5 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein |
CTD |
PMID:30102254 |
|
NCBI chr 4:157,870,493...157,883,979
Ensembl chr 4:157,881,796...157,882,950
|
|
G |
Lpar6 |
lysophosphatidic acid receptor 6 |
multiple interactions |
ISO |
lysophosphatidic acid binds to and results in increased activity of LPAR6 protein |
CTD |
PMID:18297070 |
|
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
|
|
G |
Lyve1 |
lymphatic vessel endothelial hyaluronan receptor 1 |
multiple interactions increases expression |
ISO |
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of LYVE1 protein] lysophosphatidic acid results in increased expression of LYVE1 mRNA; lysophosphatidic acid results in increased expression of LYVE1 protein |
CTD |
PMID:18642114 |
|
NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP |
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
EXP |
lysophosphatidic acid results in increased phosphorylation of MTOR protein |
CTD |
PMID:14769825 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation multiple interactions |
ISO |
lysophosphatidic acid results in increased phosphorylation of MYL9 protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:24587105 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk |
myosin light chain kinase |
affects response to substance |
ISO |
MYLK protein affects the susceptibility to lysophosphatidic acid |
CTD |
PMID:10640419 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2 |
CTD |
PMID:25398768 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein] |
CTD |
PMID:15081308 PMID:25449040 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
increases activity multiple interactions |
EXP |
lysophosphatidic acid results in increased activity of PAK1 protein 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; diphenyleneiodonium inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Genistein inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein] |
CTD |
PMID:11855845 |
|
NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383
|
|
G |
Pdpn |
podoplanin |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of PDPN mRNA; lysophosphatidic acid results in increased expression of PDPN protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PDPN protein] |
CTD |
PMID:18642114 |
|
NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of PECAM1 protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein] |
CTD |
PMID:18642114 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
multiple interactions increases activity |
ISO |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions increases activity |
EXP |
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein] |
CTD |
PMID:11243883 PMID:14769825 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation multiple interactions |
EXP |
lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Prox1 |
prospero homeobox 1 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of PROX1 mRNA; lysophosphatidic acid results in increased expression of PROX1 protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein] |
CTD |
PMID:18642114 |
|
NCBI chr13:101,669,184...101,719,804
Ensembl chr13:101,669,184...101,711,183
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of PTK2 protein [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 PMID:11792571 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of PTK2B protein |
CTD |
PMID:11792571 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rhoa |
ras homolog family member A |
increases activity multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased activity of RHOA protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein] |
CTD |
PMID:15081308 PMID:24587105 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhoc |
ras homolog family member C |
multiple interactions increases activity |
ISO |
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein] |
CTD |
PMID:24587105 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:14769825 PMID:17919812 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein] |
CTD |
PMID:17919812 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression increases secretion |
ISO |
lysophosphatidic acid results in increased expression of VEGFC mRNA lysophosphatidic acid results in increased secretion of VEGFC protein |
CTD |
PMID:18642114 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions decreases abundance |
ISO |
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of alpha-glycerophosphoric acid] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] |
CTD |
PMID:39172838 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Gk |
glycerol kinase |
multiple interactions |
EXP |
1-butyrylglycerol promotes the reaction [[GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid]; [GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid; monoacetin promotes the reaction [[GK protein results in increased metabolism of Glycerol] which results in increased chemical synthesis of alpha-glycerophosphoric acid] |
CTD |
PMID:9606984 |
|
NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631
|
|
G |
Gpd2 |
glycerol-3-phosphate dehydrogenase 2 |
multiple interactions |
ISO |
GPD2 protein inhibits the reaction [Dihydroxyacetone results in increased abundance of alpha-glycerophosphoric acid]; GPD2 protein inhibits the reaction [Glucose results in increased abundance of alpha-glycerophosphoric acid]; GPD2 protein inhibits the reaction [Glycerol results in increased abundance of alpha-glycerophosphoric acid] |
CTD |
PMID:31974165 |
|
NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901
|
|
G |
Idh2 |
isocitrate dehydrogenase (NADP(+)) 2 |
multiple interactions increases abundance |
ISO |
Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of alpha-glycerophosphoric acid] |
CTD |
PMID:27469509 |
|
NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025
|
|
G |
Ido1 |
indoleamine 2,3-dioxygenase 1 |
multiple interactions |
ISO |
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] |
CTD |
PMID:39172838 |
|
NCBI chr16:67,430,654...67,442,726
Ensembl chr16:67,430,578...67,442,730
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases abundance multiple interactions |
ISO |
MAPT protein mutant form results in decreased abundance of alpha-glycerophosphoric acid PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of alpha-glycerophosphoric acid] |
CTD |
PMID:39172838 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of alpha-glycerophosphoric acid] |
CTD |
PMID:39172838 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
[SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of RUNX2 mRNA |
CTD |
PMID:36682590 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
[SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SP7 mRNA |
CTD |
PMID:36682590 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[SAG compound co-treated with 2,4-di-tert-butylphenol co-treated with Fibroblast Growth Factor 2 co-treated with Ascorbic Acid co-treated with alpha-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SPP1 mRNA |
CTD |
PMID:36682590 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA] |
CTD |
PMID:25932594 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:23111315 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
increases hydrolysis multiple interactions increases expression increases degradation increases activity |
ISO |
ALPL protein results in increased hydrolysis of beta-glycerophosphoric acid [ALPL protein results in increased degradation of beta-glycerophosphoric acid] which results in increased abundance of Phosphates; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA; Diphosphates inhibits the reaction [[ALPL protein results in increased degradation of beta-glycerophosphoric acid] which results in increased abundance of Phosphates]; Diphosphates inhibits the reaction [ALPL protein results in increased degradation of beta-glycerophosphoric acid]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of ALPL mRNA] beta-glycerophosphoric acid results in increased expression of ALPL mRNA beta-glycerophosphoric acid results in increased activity of ALPL protein [ALPL protein results in increased hydrolysis of beta-glycerophosphoric acid] which results in increased abundance of Phosphates; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein]]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased activity of ALPL protein]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of ALPL mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased activity of ALPL protein] |
CTD |
PMID:17383965 PMID:18500657 PMID:26424790 PMID:26492236 PMID:34575692 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of ATAD2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738
|
|
G |
Atad2b |
ATPase family, AAA domain containing 2B |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ATAD2B mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 6:27,914,546...28,070,103
Ensembl chr 6:27,912,862...28,067,047
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BECN1 protein |
CTD |
PMID:23111315 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of BGLAP protein; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased secretion of BGLAP protein; Ammonium Chloride inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]]; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of BGLAP protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP protein]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA] [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of BGLAP mRNA]] |
CTD |
PMID:17692823 PMID:23111315 PMID:25932594 PMID:26492236 PMID:27028516 PMID:31935364 PMID:32473317 PMID:34562440 PMID:34575692 More...
|
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP1 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]] [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA] [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein] |
CTD |
PMID:15994055 PMID:22940495 PMID:23111315 PMID:26492236 PMID:27387537 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp3 |
bone morphogenetic protein 3 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP3 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr14:10,712,489...10,737,153
Ensembl chr14:10,712,489...10,737,153
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP7 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bmpr1a |
bone morphogenetic protein receptor type 1A |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of CEBPA protein [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA |
CTD |
PMID:14505802 PMID:25932594 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chaf1b |
chromatin assembly factor 1 subunit B |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of CHAF1B mRNA |
CTD |
PMID:26424790 |
|
NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070
|
|
G |
Cited1 |
Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of CITED1 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr X:67,350,376...67,355,072
Ensembl chr X:67,350,373...67,355,162
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of COL1A1 mRNA [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of COL1A1 mRNA] |
CTD |
PMID:31935364 PMID:34562440 PMID:34575692 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:35738543 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA] |
CTD |
PMID:25932594 PMID:35738543 |
|
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
|
|
G |
Dpf1 |
double PHD fingers 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPF1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 1:84,602,212...84,615,954
Ensembl chr 1:84,602,336...84,615,950
|
|
G |
Dppa2 |
developmental pluripotency-associated 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of DPPA2 mRNA |
CTD |
PMID:28189605 |
|
NCBI chr11:52,549,024...52,556,740
|
|
G |
Dspp |
dentin sialophosphoprotein |
multiple interactions |
ISO |
[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of DSPP mRNA] |
CTD |
PMID:35738543 |
|
NCBI chr14:5,565,562...5,571,669
Ensembl chr14:5,565,629...5,571,672
|
|
G |
Enpp1 |
ectonucleotide pyrophosphatase/phosphodiesterase 1 |
increases expression multiple interactions increases activity |
ISO |
beta-glycerophosphoric acid results in increased expression of ENPP1 mRNA Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased activity of ENPP1 protein]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of ENPP1 mRNA] |
CTD |
PMID:18500657 |
|
NCBI chr 1:20,698,746...20,763,741
Ensembl chr 1:20,698,764...20,763,715
|
|
G |
Ezh1 |
enhancer of zeste 1 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of EZH1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr10:86,126,023...86,162,001
Ensembl chr10:86,126,015...86,161,921
|
|
G |
Ezh2 |
enhancer of zeste 2 polycomb repressive complex 2 subunit |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of EZH2 protein; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of ALPL mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:26424790 |
|
NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA] |
CTD |
PMID:25062436 PMID:25932594 PMID:32473317 |
|
NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fancl |
FA complementation group L |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of FANCL mRNA |
CTD |
PMID:26424790 |
|
NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
increases expression |
ISO |
beta-glycerophosphoric acid results in increased expression of FGF23 mRNA |
CTD |
PMID:15542045 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of GCLC mRNA]] |
CTD |
PMID:27028516 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gdf10 |
growth differentiation factor 10 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of GDF10 mRNA |
CTD |
PMID:15994055 |
|
NCBI chr16:9,237,182...9,250,537
Ensembl chr16:9,237,261...9,249,343
|
|
G |
Gpc3 |
glypican 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of GPC3 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of H2AX mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Hand2 |
heart and neural crest derivatives expressed 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of HAND2 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr16:32,917,448...32,920,791
Ensembl chr16:32,917,823...32,919,891
|
|
G |
Hells |
helicase, lymphoid specific |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HELLS mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmgb2 |
high mobility group box 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of HMGB2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]]; Hydrogen Peroxide affects the reaction [Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 mRNA]; Quercetin affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of HMOX1 protein]] |
CTD |
PMID:27028516 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ibsp |
integrin-binding sialoprotein |
multiple interactions |
EXP ISO |
[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of IBSP mRNA]] [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of IBSP mRNA] |
CTD |
PMID:26492236 PMID:27028516 |
|
NCBI chr14:5,439,825...5,452,570
Ensembl chr14:5,439,829...5,452,693
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in increased expression of FABP4 mRNA |
CTD |
PMID:25062436 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of ABCA1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of CEBPA mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA; [Bexarotene co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [diazepinylbenzoic acid co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in decreased expression of ABCA1 mRNA; [LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [Rosiglitazone co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; [T0901317 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA; [tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 protein; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[LG 100268 co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; diazepinylbenzoic acid inhibits the reaction [[tributyltin co-treated with [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein]] results in increased expression of ABCA1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of DMP1 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA] [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; tetrabromobisphenol A inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of BGLAP mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of FABP4 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA] |
CTD |
PMID:25932594 PMID:32473317 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 mRNA]; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Msx2 |
msh homeobox 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of MSX2 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr17:11,097,214...11,102,879
Ensembl chr17:11,097,103...11,102,879
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein]; MTOR protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of MTOR protein] |
CTD |
PMID:23111315 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nog |
noggin |
multiple interactions |
EXP |
NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]] |
CTD |
PMID:27387537 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of NR1H3 mRNA] |
CTD |
PMID:25932594 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nsd2 |
nuclear receptor binding SET domain protein 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of NSD2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr14:76,833,179...76,911,304
Ensembl chr14:76,835,637...76,913,641
|
|
G |
Parg |
poly (ADP-ribose) glycohydrolase |
multiple interactions |
ISO |
PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein]; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of BMP2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:22940495 |
|
NCBI chr16:7,436,429...7,544,276
Ensembl chr16:7,436,476...7,544,273
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of PARP1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of PARP1 mRNA] [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein modified form; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of PARP1 protein]; PARP1 mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:22940495 PMID:26492236 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
increases expression multiple interactions |
ISO |
beta-glycerophosphoric acid results in increased expression of PHEX mRNA Foscarnet inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA]; Levamisole inhibits the reaction [beta-glycerophosphoric acid results in increased expression of PHEX mRNA] |
CTD |
PMID:18500657 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Phf2 |
PHD finger protein 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PHF2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr17:15,783,221...15,851,209
Ensembl chr17:15,781,864...15,851,208
|
|
G |
Plin1 |
perilipin 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA; Pioglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; tetrabromobisphenol A promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA]; triphenyltin hydroxide promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PLIN1 mRNA] |
CTD |
PMID:25932594 PMID:32473317 |
|
NCBI chr 1:133,664,294...133,676,854
Ensembl chr 1:133,664,892...133,676,828
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of POU5F1 mRNA |
CTD |
PMID:28189605 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA; Rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA]; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]]; Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of PPARG mRNA] |
CTD |
PMID:14505802 PMID:25932594 PMID:32473317 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PTH1R mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of PTH1R mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; MTOR protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the phosphorylation of RPS6KB1 protein] |
CTD |
PMID:23111315 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rptor |
regulatory associated protein of MTOR, complex 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased phosphorylation of RPTOR protein |
CTD |
PMID:23111315 |
|
NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO EXP |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA; [Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; [Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of RUNX2 mRNA; [Rutin co-treated with Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; Ammonium Chloride inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]]; dorsomorphin inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of RUNX2 mRNA]; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of RUNX2 mRNA]; MAP1LC3B protein affects the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; PARG mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA]; PARP1 mRNA promotes the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of RUNX2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; Sirolimus inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein]; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 mRNA; [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] co-treated with fasudil] results in increased expression of RUNX2 protein; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of RUNX2 mRNA] [Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein; [beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA; Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]; ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; Quercetin affects the reaction [Hydrogen Peroxide affects the reaction [[beta-glycerophosphoric acid co-treated with Ascorbic Acid co-treated with Dexamethasone] affects the expression of RUNX2 mRNA]] |
CTD |
PMID:17692823 PMID:22940495 PMID:23111315 PMID:26424790 PMID:26492236 PMID:27028516 PMID:27387537 PMID:31935364 PMID:32324263 PMID:32473317 PMID:34562440 PMID:34575692 PMID:35738543 More...
|
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Satb2 |
SATB homeobox 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of SATB2 mRNA] |
CTD |
PMID:26424790 |
|
NCBI chr 9:58,348,027...58,534,256
Ensembl chr 9:58,350,246...58,530,707
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA]]; Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA] |
CTD |
PMID:14505802 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Smad1 |
SMAD family member 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD1 mRNA] |
CTD |
PMID:26492236 |
|
NCBI chr19:28,513,130...28,573,665
Ensembl chr19:28,513,131...28,573,651
|
|
G |
Smad4 |
SMAD family member 4 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD4 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD4 mRNA] |
CTD |
PMID:26492236 |
|
NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438
|
|
G |
Smad5 |
SMAD family member 5 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD5 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD5 mRNA] |
CTD |
PMID:26492236 |
|
NCBI chr17:7,862,332...7,891,678
Ensembl chr17:7,864,720...7,891,634
|
|
G |
Smad9 |
SMAD family member 9 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD9 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SMAD9 mRNA] |
CTD |
PMID:26492236 |
|
NCBI chr 2:138,956,326...139,006,315
Ensembl chr 2:138,986,471...139,006,307
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SOX2 mRNA |
CTD |
PMID:28189605 |
|
NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SOX9 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with Firemaster 550] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS1 protein co-treated with triphenyl phosphate] results in decreased expression of SP7 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; [Folic Acid co-treated with Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein; Allethrins inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; d,d-T80-prallethrin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 protein]; Pioglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; quinoxyfen inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tetrabromobisphenol A inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; Tretinoin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; triphenyltin hydroxide inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA] [Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SP7 mRNA; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA; Bexarotene inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; cordycepin inhibits the reaction [pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]]; pyrrolidine dithiocarbamic acid inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of SP7 mRNA]; Rosiglitazone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA]; tributyltin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SP7 mRNA] |
CTD |
PMID:22940495 PMID:25062436 PMID:25932594 PMID:26492236 PMID:32324263 PMID:32473317 PMID:34575692 More...
|
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
multiple interactions |
ISO |
[Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPARC protein |
CTD |
PMID:17692823 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO |
[Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of SPP1 protein; [Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA; PARG mRNA inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid co-treated with Cholecalciferol] results in increased expression of SPP1 mRNA] [Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SPP1 mRNA; N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride inhibits the reaction [[Ascorbic Acid co-treated with Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of SPP1 mRNA] |
CTD |
PMID:17692823 PMID:22940495 PMID:26492236 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] affects the expression of SQSTM1 protein |
CTD |
PMID:23111315 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of PPARG mRNA]]; SRC protein promotes the reaction [Tetrachlorodibenzodioxin inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of SCD1 mRNA]] |
CTD |
PMID:14505802 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA; bexarotene promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; rosiglitazone promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA]; tributyltin promotes the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone co-treated with INS protein] results in increased expression of SREBF1 mRNA] |
CTD |
PMID:25932594 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stc1 |
stanniocalcin 1 |
decreases expression |
EXP |
beta-glycerophosphoric acid results in decreased expression of STC1 mRNA |
CTD |
PMID:17438129 |
|
NCBI chr15:44,299,591...44,311,695
Ensembl chr15:44,299,621...44,310,264
|
|
G |
Suv39h1 |
SUV39H1 histone lysine methyltransferase |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr X:14,421,028...14,433,993
Ensembl chr X:14,421,109...14,433,982
|
|
G |
Suv39h1-ps1 |
SUV39H1 histone lysine methyltransferase, pseudogene 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr X:141,792,589...141,795,257
|
|
G |
Suv39h2 |
SUV39H2 histone lysine methyltransferase |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of SUV39H2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr17:74,756,290...74,775,332
Ensembl chr17:74,756,306...74,775,332
|
|
G |
Tafazzin |
tafazzin, phospholipid-lysophospholipid transacylase |
multiple interactions |
ISO |
[Cholecalciferol co-treated with beta-glycerophosphoric acid co-treated with Ascorbic Acid] results in increased expression of TAFAZZIN mRNA |
CTD |
PMID:17692823 |
|
NCBI chr X:152,065,539...152,076,178
Ensembl chr X:152,065,609...152,074,001
|
|
G |
Tcf19 |
transcription factor 19 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of TCF19 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271
|
|
G |
Tcf20 |
transcription factor 20 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TCF20 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 7:113,953,449...114,104,166
Ensembl chr 7:113,954,089...114,051,839
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA; EZH2 protein inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of TNFRSF11B mRNA] |
CTD |
PMID:26424790 |
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of and results in increased secretion of TNFSF11 protein |
CTD |
PMID:32156525 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Uhrf1 |
ubiquitin-like with PHD and ring finger domains 1 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in decreased expression of UHRF1 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631
|
|
G |
Uhrf2 |
ubiquitin like with PHD and ring finger domains 2 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of UHRF2 mRNA |
CTD |
PMID:26424790 |
|
NCBI chr 1:227,814,639...227,877,907
Ensembl chr 1:227,814,963...227,877,904
|
|
G |
Vcl |
vinculin |
multiple interactions |
ISO |
[Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of VCL protein; Hydroxychloroquine inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of VCL protein] |
CTD |
PMID:28975700 |
|
NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606
|
|
G |
Wnt1 |
Wnt family member 1 |
multiple interactions |
ISO |
[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of WNT1 mRNA; lead nitrate inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid co-treated with ascorbate-2-phosphate] results in increased expression of WNT1 mRNA] |
CTD |
PMID:35738543 |
|
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
|
|
G |
Wnt11 |
Wnt family member 11 |
multiple interactions |
ISO |
[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of WNT11 mRNA; cadmium sulfate inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid co-treated with Dexamethasone] results in increased expression of WNT11 mRNA] |
CTD |
PMID:28189605 |
|
NCBI chr 1:153,134,503...153,154,294
Ensembl chr 1:153,138,197...153,154,294
|
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity |
ISO |
Isosorbide Dinitrate results in decreased activity of CYP1A1 protein |
CTD |
PMID:33814510 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO |
[Isosorbide Dinitrate co-treated with Plant Preparations] results in decreased expression of EDN1 mRNA |
CTD |
PMID:15719745 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
decreases response to substance |
ISO |
G6PD protein results in decreased susceptibility to Isosorbide Dinitrate |
CTD |
PMID:6401899 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
[Isosorbide Dinitrate co-treated with Ascorbic Acid] affects the expression of NOS3 mRNA; [Isosorbide Dinitrate co-treated with Plant Preparations] results in increased expression of NOS3 mRNA |
CTD |
PMID:15719745 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
|
G |
Pafah1b1 |
platelet-activating factor acetylhydrolase 1b, regulatory subunit 1 |
multiple interactions |
EXP |
isosorbide-5-mononitrate inhibits the reaction [Castor Oil results in increased expression of PAFAH1B1 protein] |
CTD |
PMID:8738301 |
|
NCBI chr10:59,533,042...59,591,808
Ensembl chr10:59,534,117...59,591,808
|
|
|
G |
Ddr1 |
discoidin domain receptor tyrosine kinase 1 |
|
ISO |
lysophosphatidic acid increased expression of Ddr1 in 3T3 and GD25 cells |
RGD |
PMID:28199848 |
RGD:151347403 |
NCBI chr20:3,042,494...3,064,442
Ensembl chr20:3,044,320...3,064,468
|
|
G |
Prkd1 |
protein kinase D1 |
increases phosphorylation |
EXP |
LPA increases phosphorylation of Prkd1 protein in neonatal ventricular myocytes |
RGD |
PMID:16648482 |
RGD:243065275 |
NCBI chr 6:67,725,193...68,039,002
Ensembl chr 6:67,725,905...68,039,042
|
|